3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
2
Lymphoma
2
Recurrence
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Diarrhea
1
Colorectal Neoplasms
1
Interventions
Rituximab
24
Cyclophosphamide
14
fludarabine
8
Etoposide
6
Vincristine
5
Prednisone
5
Doxorubicin
5
fludarabine phosphate
4
Carboplatin
4
venetoclax
3
obinutuzumab
3
ibrutinib
3
atezolizumab
3
Whole-Body Irradiation
3
Mycophenolic Acid
3
Lenalidomide
3
Ifosfamide
3
Cytarabine
3
Carmustine
3
Bortezomib
3
Bendamustine Hydrochloride
3
ublituximab
2
pembrolizumab
2
pegfilgrastim
2
ibritumomab tiuxetan
2
Tiragolumab
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Indium
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, B-Cell
×
Drugs, Investigational
×
Clear all
NCT05972720
2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2
Terminated
101 enrolled